FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (Fezolinetant) for Hot Flashes Due to Menopause

Why It Matters

The added warning could curb Veozah’s rapid adoption and prompt clinicians to favor alternative therapies, while heightened monitoring may increase healthcare costs and patient burden.

Key Takeaways

• FDA adds Boxed Warning for Veozah liver injury risk.
• Monthly liver tests required for first three months of therapy.
• Patients must stop Veozah at first sign of liver symptoms.
• Post‑marketing case showed severe enzyme elevations within 40 days.
• About 28,700 U.S. patients filled Veozah prescription May 2024.

Pulse Analysis

Menopause‑related hot flashes affect millions of women, and the therapeutic arsenal has traditionally been dominated by hormone‑replacement therapy (HRT). In May 2023, the FDA approved Veozah (fezolinetant), the first oral, non‑hormonal neurokinin‑3 receptor antagonist, offering an alternative for patients who cannot or choose not to use estrogen. Its mechanism—blocking neurokinin‑B signaling to stabilize hypothalamic temperature control—generated strong commercial interest, with roughly 28,700 prescriptions filled in May 2024 alone. The recent Boxed Warning, however, injects a safety caveat that could reshape clinician confidence in this novel class.

The FDA’s mandate for baseline liver panels and monthly testing during the first three months, then at months six and nine, reflects a precautionary approach to the rare but severe hepatotoxicity observed in a post‑marketing case. Practically, physicians must integrate additional lab orders, educate patients on jaundice symptoms, and be prepared to discontinue therapy at the first sign of injury. Compared with HRT, which carries its own cardiovascular and cancer risks, Veozah now presents a trade‑off between non‑hormonal efficacy and intensified monitoring costs, potentially nudging prescribers toward established alternatives for low‑risk patients.

From a regulatory perspective, the Boxed Warning sets a precedent for heightened surveillance of emerging hormone‑modulating agents, signaling that post‑market data will continue to drive label revisions. Pharmaceutical sponsors may need to invest in real‑world evidence studies to quantify the incidence of liver events and reassure payers. For patients, transparent communication about liver‑related signs and the importance of timely lab work becomes essential to maintain adherence. As the NK3 antagonist pipeline matures, manufacturers will likely prioritize safety profiling to avoid similar setbacks, while the market may see a modest slowdown in Veozah’s growth trajectory.